tiakis Biotech AG Reports Clinical Phase Ib/II Trial Results of Tiprelestat for the Treatment of Hospitalized COVID-19 Patients. Tiprelestat was safe and well tolerated, with initial signs of clinical efficacy. Great news on tiakis´ lead program, Martin Voss, Michael Motz and team! https://lnkd.in/edbxppzA #COVID #COVID19 #hospitalized #clinicalstudy #clinicaldata #tiprelestat
Ines-Regina Buth’s Post
More Relevant Posts
-
Creative B2B marketing, communications and branding. Trend scout at the intersection of industry and design.
Making rare disease drug development happen, and happen faster, by looking at rare disease drug development paradigms, and how to shift them. All explained in Volv Global SA's talk at the World Orphan Drug Congress Europe 2024, next Wednesday - see you there!
You can't understand what's really important to the people in the healthcare ecosystem without talking to them directly. For a few years now, Volv Global SA has been consulting with key stakeholders on the challenges and what's needed to change the paradigms for rare disease drug development. At the World Orphan Drug Congress Europe 2024, our CEO 💭 Christopher Rudolf will present our findings to-date! "Drive for change: paradigm shifts to accelerate rare disease drug development" - Wednesday, 23rd October, 4.10 p.m., at Theater 5 (Precision Medicine track). Details in the comments! #driveforchange #paradigmshift #drugdevelopment #raredisease #orphandrug #volvglobal #christopherrudolf #wodc2024 #worldorphandrugcongress
-
🗺 Want to catch up on Day 2 of World Orphan Drug Congress? Check out our Remap Consulting summary below 👇 #WODC2024 #EUHTA #MarketAccess
What a jam-packed day at Fira de Barcelona! 🎉 Day 2 at the World Orphan Drug Congress Europe 2024 brought compelling insights from expert speakers during two fascinating keynotes, focused on the rare disease integration and patient centricity. 🔑 Key takeaway from the 𝐑𝐚𝐫𝐞 𝐃𝐢𝐬𝐞𝐚𝐬𝐞 𝐀𝐜𝐭𝐢𝐨𝐧 𝐏𝐥𝐚𝐧 𝐤𝐞𝐲𝐧𝐨𝐭𝐞: The panel explored how national and EU-level strategies can align to create real impact in rare disease policies. The focus was on collaboration, learning from countries already implementing action plans, and closing gaps in patient care and drug development. 🔑 Key takeaway from the 𝐏𝐚𝐭𝐢𝐞𝐧𝐭 𝐕𝐨𝐢𝐜𝐞 𝐤𝐞𝐲𝐧𝐨𝐭𝐞: The discussion underscored the increasing importance of patient involvement in shaping policy and clinical trials for rare diseases. While progress has been made, the need to formalise patient engagement and involve them earlier is critical to ensure trials and policies truly reflect patient experiences. 📥 Want the full report? Download it here ➡ https://lnkd.in/e4zQcdic #WODC2024 #RareDiseases #PatientAccess #Healthcare #MarketAccess #Pharma #EUHTA #Patients #OrphanDrugs
-
Join us today at #WCLC24 with Dr. Enriqueta Felip to explore patient-reported outcomes in patients with previously treated KRASG12C-mutated #NSCLC in the Phase 3 KRYSTAL-12 clinical trial. Does the previously reported efficacy benefit of a #KRAS inhibitor also lead to an improvement in heath-related quality of life? #LCSM https://bit.ly/3MBShG2
-
-
Translational Science Lead at AstraZeneca | Immunology | Cell Therapy | Oncology | Precision Medicine | Biomarker Discovery
Care for lupus patients is evolving, with innovation accelerating in recent years. At AstraZeneca, we’re working closely with experts such as Dr Ian Bruce and Dr Julia Weinmann-Menke, who recently shared their insightful opinions on the following in an EMJ article: • Current state of SLE care • Recent updates to clinical recommendations elevating earlier intervention and steroid-tapering • Achieving remission as a key care goal Read this interesting piece here: https://bit.ly/4hl8yNM #MakeLupusVisible #TransformLupus
-
-
Associate Principal Scientist Inhalation, TOSI, Global Operations, AstraZeneca, Macclesfield
Care for lupus patients is evolving, with innovation accelerating in recent years. At AstraZeneca, we’re working closely with experts such as Dr Ian Bruce and Dr Julia Weinmann-Menke, who recently shared their insightful opinions on the following in an EMJ article: • Current state of SLE care • Recent updates to clinical recommendations elevating earlier intervention and steroid-tapering • Achieving remission as a key care goal Read this interesting piece here: https://bit.ly/4hl8yNM #MakeLupusVisible #TransformLupus
-
-
Care for lupus patients is evolving, with innovation accelerating in recent years. At AstraZeneca, we’re working closely with experts such as Dr Ian Bruce and Dr Julia Weinmann-Menke, who recently shared their insightful opinions on the following in an EMJ article: • Current state of SLE care • Recent updates to clinical recommendations elevating earlier intervention and steroid-tapering • Achieving remission as a key care goal Read this interesting piece here: https://bit.ly/4hl8yNM #MakeLupusVisible #TransformLupus
-
-
Care for lupus patients is evolving, with innovation accelerating in recent years. At AstraZeneca, we’re working closely with experts such as Dr Ian Bruce and Dr Julia Weinmann-Menke, who recently shared their insightful opinions on the following in an EMJ article: • Current state of SLE care • Recent updates to clinical recommendations elevating earlier intervention and steroid-tapering • Achieving remission as a key care goal Read this interesting piece here: https://bit.ly/4hl8yNM #MakeLupusVisible #TransformLupus
-
-
Care for lupus patients is evolving, with innovation accelerating in recent years. At AstraZeneca, we’re working closely with experts such as Dr Ian Bruce and Dr Julia Weinmann-Menke, who recently shared their insightful opinions on the following in an EMJ article: • Current state of SLE care • Recent updates to clinical recommendations elevating earlier intervention and steroid-tapering • Achieving remission as a key care goal Read this interesting piece here: https://bit.ly/4hl8yNM #MakeLupusVisible #TransformLupus
-
-
Care for lupus patients is evolving, with innovation accelerating in recent years. At AstraZeneca, we’re working closely with experts such as Dr Ian Bruce and Dr Julia Weinmann-Menke, who recently shared their insightful opinions on the following in an EMJ article: • Current state of SLE care • Recent updates to clinical recommendations elevating earlier intervention and steroid-tapering • Achieving remission as a key care goal Read this interesting piece here: https://bit.ly/4hl8yNM #MakeLupusVisible #TransformLupus
-